Discovery of a New Class of Uracil Derivatives as Potential Mixed Lineage Kinase Domain-like Protein (MLKL) Inhibitors
作者:Bo Cui、Bo Yan、Kang Wang、Lin Li、She Chen、Zhiyuan Zhang
DOI:10.1021/acs.jmedchem.2c00548
日期:2022.10.13
programmed cell death. Mixed lineage kinase domain-like protein (MLKL) is the necroptosis executor, and it is involved in various diseases such as tissue damage and neurodegeneration-related diseases. Here, we report the development of novel MLKL inhibitors with a uracil nucleus through scaffold morphing from our previously reported xanthine MLKL inhibitor TC13172. After a rational structure–activity relationship
坏死性凋亡是程序性细胞死亡的一种形式。混合谱系激酶域样蛋白(MLKL)是坏死性凋亡的执行者,它参与多种疾病,如组织损伤和神经退行性疾病相关疾病。在这里,我们报告了通过支架变形从我们之前报道的黄嘌呤 MLKL 抑制剂 TC13172 开发出具有尿嘧啶核的新型 MLKL 抑制剂。经过合理的构效关系研究,我们得到了高效化合物56和66。机理研究表明,这些化合物部分抑制了 MLKL 寡聚化,并显着抑制了 MLKL 易位至膜。与 TC13172、56和66相比具有不同的作用方式,重要的是,它们与谷胱甘肽的反应速率低 150 倍以上。这种潜在脱靶效应和细胞毒性的降低使该系列成为进一步开发 MLKL 相关疾病治疗药物的有吸引力的起点。